Login to Your Account



FDA Also Approves Psoriasis Drug Stelara

Allos' Folotyn Wins Accelerated PTCL Nod; More Trials to Come

By By Jennifer Boggs


Monday, September 28, 2009
Even as Allos Therapeutics Inc. prepares for the commercial launch of Folotyn in relapsed, refractory peripheral T-cell lymphoma following accelerated FDA approval, the Westminster, Colo.-based firm already has its sights set on expanding the targeted antifolate drug into broader the T-cell lymphoma space and other cancer indications. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription